

**PERCHERON APPOINTS DR CATHRYN CLARY
AS CHIEF MEDICAL ADVISOR**

Melbourne, Australia – 3 June 2024: Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce the appointment of Cathryn Clary, MD, MBA, as Chief Medical Advisor, with immediate effect.

Dr Clary is a highly experienced drug development physician. After completing her medical training, she spent thirteen years working with Pfizer, Inc (NYSE: PFE) in New York, NY, where she rose to the position of Senior Vice President, US Medical. She went on to hold senior roles with Ipsen Biopharmaceuticals, Inc, and with Novartis AG (NYSE: NVS).

More recently, she has served as a consultant to emerging biotechnology companies, including a two-year engagement as Consulting Chief Medical Officer at Solid Biosciences (NASDAQ: SLDB), where she oversaw that company’s gene therapy program in Duchenne muscular dystrophy. Dr Clary holds a Bachelor of Arts degree (cum laude) from Bryn Mawr College, a Medical Doctorate from the University of Missouri-Columbia, and a Master of Business Administration from the University of Delaware. She is based in New Jersey.

“We are thrilled to have an industry veteran like Cathryn join the Percheron team,” commented Percheron CEO, Dr James Garner. “With recruitment to our phase IIb trial now complete, the team is turning its attention to next steps, including potential engagement with regulatory agencies such as FDA. Cathryn’s wealth of experience, including her impressive track record in Duchenne muscular dystrophy, will be an enormous asset for the company as we prepare for the next chapter in the development of ATL1102. In addition, Cathryn’s extensive networks among clinicians and patient advocacy in the United States will be very helpful as we work to establish ATL1102 as one of the most exciting late-clinical-stage prospects in this challenging disease area.”

Dr Clary will initially join the team in a part-time consulting role, with the opportunity to expand her position as momentum grows in the ATL1102 program.

“I am delighted to join the Percheron team,” commented Dr Clary. “Having previously worked first-hand in the Duchenne field, I am acutely aware of the need for new therapies in this disease. I am excited by the potential ATL1102 has shown to date, and I look forward to working with the team to help ensure its success. The next six to twelve months will no doubt be a transformative period for Percheron.”

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

*This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.*
